AMIGO2
Amphoterin-induced protein 2
Also known as: ALI1, AMGO2_HUMAN, DEGA
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q86SJ2
- Gene
- AMIGO2
- Ensembl
- ENSG00000139211
- Chromosome
- 12
- Canonical length
- 522 aa
- Protein class
- Predicted membrane proteins
- Subcellular location
- Golgi apparatus,Plasma membrane,Cytosol
OverviewNCBI Gene
Predicted to be involved in several processes, including heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules; homophilic cell adhesion via plasma membrane adhesion molecules; and positive regulation of synapse assembly. Predicted to be located in nucleus and plasma membrane. Predicted to be active in membrane. Biomarker of gastric adenocarcinoma. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
522 residues, UniProt reviewed canonical sequence.
>Q86SJ2|AMIGO2
1 MSLRVHTLPT LLGAVVRPGC RELLCLLMIT VTVGPGASGV CPTACICATD IVSCTNKNLS
61 KVPGNLFRLI KRLDLSYNRI GLLDSEWIPV SFAKLNTLIL RHNNITSIST GSFSTTPNLK
121 CLDLSSNKLK TVKNAVFQEL KVLEVLLLYN NHISYLDPSA FGGLSQLQKL YLSGNFLTQF
181 PMDLYVGRFK LAELMFLDVS YNRIPSMPMH HINLVPGKQL RGIYLHGNPF VCDCSLYSLL
241 VFWYRRHFSS VMDFKNDYTC RLWSDSRHSR QVLLLQDSFM NCSDSIINGS FRALGFIHEA
301 QVGERLMVHC DSKTGNANTD FIWVGPDNRL LEPDKEMENF YVFHNGSLVI ESPRFEDAGV
361 YSCIAMNKQR LLNETVDVTI NVSNFTVSRS HAHEAFNTAF TTLAACVASI VLVLLYLYLT
421 PCPCKCKTKR QKNMLHQSNA HSSILSPGPA SDASADERKA GAGKRVVFLE PLKDTAAGQN
481 GKVRLFPSEA VIAEGILKST RGKSDSDSVN SVFSDTPFVA STLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AMIGO2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 68 nTPM
Expression across tissuesHPA
Tissue
- blood vessel: 68 nTPM
- colon: 33 nTPM
- smooth muscle: 32 nTPM
- fallopian tube: 31 nTPM
- endometrium: 24 nTPM
- ovary: 24 nTPM
Single-cell type
- breast myoepithelial cells: 109 nCPM
- platelets: 96 nCPM
- epididymal basal cells: 92 nCPM
- endometrial glandular cells: 86 nCPM
- urothelial cells: 74 nCPM
- smooth muscle cells: 60 nCPM
Immune cell
- naive CD4 T-cell: 15 nTPM
- naive CD8 T-cell: 12 nTPM
- plasmacytoid DC: 8.8 nTPM
- NK-cell: 8.6 nTPM
- memory CD8 T-cell: 6.9 nTPM
- memory CD4 T-cell: 6.8 nTPM
Brain region
- midbrain: 75 nTPM
- pons: 40 nTPM
- hypothalamus: 25 nTPM
- medulla oblongata: 18 nTPM
- cerebral cortex: 12 nTPM
- basal ganglia: 8.3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.55
- gnomAD pLI
- 0.6
- gnomAD missense Z
- 0.98
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- brain development
- heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules
- homophilic cell adhesion via plasma membrane adhesion molecules
- negative regulation of programmed cell death
- positive regulation of synapse assembly
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Cysteine-rich flanking region, C-terminal
- Leucine-rich repeat
- Leucine-rich repeat, typical subtype
- Immunoglobulin domain subtype
- Immunoglobulin-like domain
- Immunoglobulin-like fold
- Amphoterin-induced protein
- Leucine-rich repeat domain superfamily
- Immunoglobulin-like domain superfamily
- Leucine rich repeat
- Immunoglobulin domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of AMIGO2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AMIGO2 as an antibody target. Whether an autoantibody or antibody against AMIGO2 could matter depends on whether native AMIGO2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AMIGO2 is annotated at the cell surface, where native AMIGO2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label AMIGO2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...